Cure8 research brief
If you have Crohn’s disease with perianal fistulas and are treated with infliximab, this study suggests the drug is cleared faster and trough levels are often lower after standard dosing — which may mean you need higher or more frequent dosing to reach target concentrations linked with better fistula healing.
Patients with perianal fistulizing Crohn’s disease, clinicians who manage biologic dosing for IBD, pharmacists, and researchers studying biologic pharmacokinetics and therapeutic‑drug‑monitoring.
Perianal fistulizing Crohn’s disease (PFCD) was associated with higher infliximab clearance and lower trough levels after standard induction dosing in this population PK study (ATLANTIC).
The report used a two-compartment nonlinear mixed-effects model on 148 patients (62 PFCD, 86 luminal CD) with serial IFX trough and anti‑drug antibody measurements through week 52. After adjustment for dose, weight, albumin, and antibodies, IFX clearance was ~23% higher in patients with progressive perianal fistulas during the first 14 weeks.
Fewer PFCD patients achieved recommended target troughs during induction. What this means: in people with active perianal fistulas, standard infliximab dosing more often produced lower or subtherapeutic drug concentrations, which may help explain why dose intensification is frequently needed for fistulizing disease.
These results are grounded in the study abstract and modeled pharmacokinetic analysis provided by the authors.
Limitations and next steps: the abstract reports model-based findings from the study cohort; full paper review is needed for details about concomitant immunomodulator use, exact target trough definitions, clinical outcomes linked to concentrations, and generalizability to other IFX regimens or biosimilars.
Clinical decisions about dosing should be made with a treating clinician and, when available, therapeutic‑drug‑monitoring data.
This classification and curator note are based on the article abstract (structured content depth: abstract). The findings reflect modeled pharmacokinetic differences in the study cohort; they do not by themselves define new dosing recommendations. Therapeutic decisions should rely on full study data, clinical context, and clinician judgment.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Leona M. and Harry B. Helmsley Charitable Trust
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study suggests starting anti-TNF drugs early in children with Crohn's could strongly lower the chance of developing anal fistulas, a serious complication that often requires surgery. Preventing fistulas can reduce...
Perianal fistulizing Crohn's disease is a disabling complication; a subcutaneous form of infliximab could lower treatment burden and expand options if its effectiveness and safety in this specific setting are confirmed.
Perianal fistulas are a common, hard-to-heal complication of Crohn's disease. This review collects current options beyond infliximab and explains where evidence is stronger or still emerging, which can help patients and...
